Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.
EleanoredReinhardt

Ipsen Announces Data Presentations For Somatuline® Depot (lanreotide) In Gastroenteropancreatic Neuroendocrine Tumors At American Society Of Clinical Oncology Annual Meeting - Yahoo Finance

gallstone picture alternative gallstone treatment to 11:30 a.m., S Hall A Indication Somatuline Depot (lanreotide) Injection 120 mg is indicated for the treatment of adult patients with unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. Important Safety Information Contraindications: Somatuline is contraindicated in patients with hypersensitivity to lanreotide. Allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide. Warnings and Precautions: Cholelithiasis and Gallbladder Sludge: Somatuline may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Hypoglycemia or Hyperglycemia: Pharmacological studies show that Somatuline, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon. Blood glucose levels should 2 cm gallstone be monitored when Somatuline treatment is initiated, or when the dose is altered, and antidiabetic treatment should be adjusted accordingly.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/ipsen-announces-data-presentations-somatuline-131700333.html

Don't be the product, buy the product!

Schweinderl